Science and medicine have come a long way in recent years, and one exciting development is the use of in-utero enzyme replacement therapy (ERT) to treat certain rare genetic disorders. ERT is a treatment that replaces missing or defective enzymes in the body, and it has been used successfully for a number of lysosomal storage disorders (LSDs), such as Gaucher disease and Fabry disease. However, for some LSDs, ERT may not be effective or may not be able to reach the affected tissues. In utero ERT offers a promising alternative for some of these conditions, as it allows the therapeutic enzyme to be delivered to the developing fetus during pregnancy.
In utero ERT involves injecting the therapeutic enzyme directly into the amniotic fluid surrounding the fetus. The hope is that the enzyme will be absorbed by the fetus and improve outcomes at birth and beyond. While in utero ERT is still a relatively new and experimental treatment, recent research has shown that it can be safe and effective for certain LSDs.
One of the most promising aspects of in utero ERT is its potential to prevent or reduce the severity of symptoms in infants with certain LSDs. For example, in a study published in the Journal of Clinical Investigation, in utero ERT was used to treat two LSDs, mucopolysaccharidosis type VII (MPS VII) and Pompe disease. The researchers found that in utero ERT was safe and feasible for both conditions, and that it improved clinical outcomes for some of the infants who received it. Similar studies have shown promising results for other LSDs, such as Niemann-Pick disease type C and Gaucher disease.
While the results of these studies are encouraging, in utero ERT is not without risks. There is a risk of infection associated with the procedure, and there is also a risk of damage to the fetus. Additionally, in utero ERT is a highly specialized procedure that requires a team of skilled medical professionals. Not all medical centers have the expertise to perform the procedure, which may limit its availability to some families.
Despite these challenges, in utero ERT offers hope to families affected by rare genetic disorders. It is a remarkable example of how science and medicine can come together to offer new treatment options and improve outcomes for patients. In the case of in utero ERT, the potential benefits extend beyond the individual patient to future generations, as it may prevent or reduce the likelihood of passing on the genetic disorder to offspring.
In conclusion, in utero ERT is an exciting development in the field of medicine and a promising treatment option for certain rare genetic disorders. While more research is needed to fully understand the risks and benefits of the procedure, early studies have shown that it can be safe and effective for some LSDs. As science and medicine continue to advance, it is likely that we will see even more innovative treatments emerge that offer hope to patients and families affected by rare and debilitating conditions.
References:
- Hershkovitz T, et al. In utero enzyme replacement therapy rescues prenatal lethality in a murine model of mucopolysaccharidosis type VII. Sci Transl Med. 2013;5(203):203ra127.
- Matte U, et al. Intrauterine Enzyme Replacement Therapy: A Lifeline for Patients with Lysosomal Storage Diseases. JIMD Rep. 2021;59(1):6-13.
- Harmatz P, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2004;
El Camino Women’s Medical Group offers the latest Minimally Invasive Solutions for gynecologic problems. Drs. Amy Teng, Erika Balassiano, Pooja Gupta, and Christina Lam, all members of AAGL (American Association of Gynecologic Laparoscopy), are highly trained and experienced in the field of Minimally Invasive Gynecologic Surgery. Dr. Erika Balassiano has also completed a Minimally Invasive Gynecologic Surgery Fellowship under the supervision of world-renowned Dr. Camran Nezhat.
All of our physicians are El Camino Hospital doctors and operate and deliver at the Mountain View campus.
Serving Mountain View, Los Altos, Los Altos Hills, Atherton, Palo Alto, Redwood City, Burlingame, Saratoga, Cupertino, Sunnyvale, Los Gatos, Campbell, San Jose, Santa Clara, Silicon Valley, Milpitas, Fremont, South Bay, East Bay, and North Bay.